StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)

Equities researchers at StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the stock.

Can-Fite BioPharma Stock Performance

Shares of CANF opened at $2.10 on Friday. The firm’s 50-day moving average price is $2.16 and its 200-day moving average price is $2.14. The firm has a market capitalization of $7.43 million, a price-to-earnings ratio of -1.17 and a beta of 1.53. Can-Fite BioPharma has a 1-year low of $1.66 and a 1-year high of $3.33.

Can-Fite BioPharma (NYSE:CANF) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. On average, research analysts forecast that Can-Fite BioPharma will post -0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Can-Fite BioPharma

Several hedge funds have recently bought and sold shares of the business. Armistice Capital LLC bought a new stake in Can-Fite BioPharma during the fourth quarter worth about $340,000. Schechter Investment Advisors LLC purchased a new position in Can-Fite BioPharma in the fourth quarter worth about $44,000. Finally, Virtu Financial LLC purchased a new position in Can-Fite BioPharma in the second quarter worth about $52,000. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.